Trial site
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
Lublin, Lublin Voivodeship 20-954, PolandEU-13 widening countryNot linked to an institution yet
- 17running trials
- 16closed trials
The trials here
What the 33 trials at this site are about, from their registry records.
- Phase
- Phase 321 trials
- Phase 27 trials
- Phase 11 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed14 trials
- Active, not recruiting12 trials
- Recruiting4 trials
- Terminated2 trials
- Enrolling by invitation1 trial
- Lead sponsor
- AstraZeneca3 trials
- Eli Lilly and Company3 trials
- Amgen2 trials
- Bristol-Myers Squibb2 trials
- Takeda2 trials
- and 21 more
Running trials
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Recruiting
Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial.
2023-506452-25-00· Phase 2· Medical University Of Lodz· Source
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866· Phase 3· Amgen· Source
Recruiting
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects
with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
2024-511309-47-00· Phase 2· Karyopharm Therapeutics Inc.· Source
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806· Phase 2· Karyopharm Therapeutics Inc· Source
Contact: Krzysztof Giannopoulos
Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
NCT05735327· Takeda· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494· Phase 3· AstraZeneca· Source
Enrolling by invitation
Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions
NCT05305612· Phase 4· National Institute of Cardiology, Warsaw, Poland· Source
Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04612751· Phase 1· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error